Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
SUMMARYFungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, and their utility and efficacy in antifungal treatment are limited by one or more of innate or acquired resistance in some fungi, poor penetration into "sequestered" sites, and agent-specific side effect which require frequent patient reassessment and monitoring. Agents with novel mechanisms, favorable pharmacokinetic (PK) profiles including good oral bioavailability, and fungicidal mechanism(s) are urgently needed. Here, we provide a comprehensive review of novel antifungal agents, with both improved known mechanisms of actions and new antifungal classes, currently in clinical development for treating invasive yeast, mold (filamentous fungi), Pneumocystis jirovecii infections, and dimorphic fungi (endemic mycoses). We further focus on inhaled antifungals and the role of immunotherapy in tackling fungal infections, and the specific PK/pharmacodynamic profiles, tissue distributions as well as drug-drug interactions of novel antifungals. Finally, we review antifungal resistance mechanisms, the role of use of antifungal pesticides in agriculture as drivers of drug resistance, and detail detection methods for antifungal resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical microbiology reviews - (2024) vom: 11. Apr., Seite e0007423 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoenigl, Martin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 11.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1128/cmr.00074-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370917286 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370917286 | ||
| 003 | DE-627 | ||
| 005 | 20240411233422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/cmr.00074-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370917286 | ||
| 035 | |a (NLM)38602408 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoenigl, Martin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a SUMMARYFungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, and their utility and efficacy in antifungal treatment are limited by one or more of innate or acquired resistance in some fungi, poor penetration into "sequestered" sites, and agent-specific side effect which require frequent patient reassessment and monitoring. Agents with novel mechanisms, favorable pharmacokinetic (PK) profiles including good oral bioavailability, and fungicidal mechanism(s) are urgently needed. Here, we provide a comprehensive review of novel antifungal agents, with both improved known mechanisms of actions and new antifungal classes, currently in clinical development for treating invasive yeast, mold (filamentous fungi), Pneumocystis jirovecii infections, and dimorphic fungi (endemic mycoses). We further focus on inhaled antifungals and the role of immunotherapy in tackling fungal infections, and the specific PK/pharmacodynamic profiles, tissue distributions as well as drug-drug interactions of novel antifungals. Finally, we review antifungal resistance mechanisms, the role of use of antifungal pesticides in agriculture as drivers of drug resistance, and detail detection methods for antifungal resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a fungal disease | |
| 700 | 1 | |a Arastehfar, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Arendrup, Maiken Cavling |e verfasserin |4 aut | |
| 700 | 1 | |a Brüggemann, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Agostinho |e verfasserin |4 aut | |
| 700 | 1 | |a Chiller, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Egger, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Feys, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Gangneux, Jean-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Gold, Jeremy A W |e verfasserin |4 aut | |
| 700 | 1 | |a Groll, Andreas H |e verfasserin |4 aut | |
| 700 | 1 | |a Heylen, Jannes |e verfasserin |4 aut | |
| 700 | 1 | |a Jenks, Jeffrey D |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Lagrou, Katrien |e verfasserin |4 aut | |
| 700 | 1 | |a Lamoth, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Prattes, Juergen |e verfasserin |4 aut | |
| 700 | 1 | |a Sedik, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Wauters, Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Wiederhold, Nathan P |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, George R |c 3rd |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology reviews |d 1996 |g (2024) vom: 11. Apr., Seite e0007423 |w (DE-627)NLM012914312 |x 1098-6618 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:04 |g pages:e0007423 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/cmr.00074-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 04 |h e0007423 | ||